Bristol, Merck checkpoint inhibitors focus of FDA advisory committee meeting
An FDA advisory panel on Bristol Myers Squibb Opdivo and Merck Keytruda will examine if PD-L1 tumor expression should limit ...
bovnews2d
Bristol-Myers Squibb Co (BMY) Stock Rated Equal Weight by Barclays
On Monday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $50.01 which represents a slight increase of $0.60 or 1.21% from the prior close of $49.41. The stock opened at ...
BioPharma Dive4d
Novo sinks on obesity drug results; Sanofi reveals anticipated MS data
A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged.
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day
Bristol Myers Squibb Co. closed $10.05 below its 52-week high ($59.46), which the company reached on September 22nd.
Armed robbery in Revesby6d
$6.8M Grant Boosts Replication of KY Lung Cancer Success
A groundbreaking lung cancer screening project co-led by the University of Kentucky Markey Cancer Center and the University of Colorado (CU) Cancer ...
Le Lézard6d
New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis
Bristol Myers Squibb today announced new data from the Phase 3 DAYBREAK trial demonstrating that decreased rates of brain volume loss were sustained in the open-label extension (OLE) for patients ...